Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung condition characterised by diffuse alveolar damage, increased capillary permeability and severe hypoxaemia refractory to oxygen ...

CHICAGO -- Classifying inflammatory subphenotypes of acute respiratory distress syndrome (ARDS) with bedside lab testing was feasible and showed differences in 60-day mortality, according to a ...

Drawing from research on sepsis and complement biology, they developed the monoclonal antibody vilobelimab to block overactive inflammatory responses in patients with severe inflammatory diseases ...

FibroBiologics is now evaluating its fibroblast platform in Hantavirus disease models, with particular emphasis on inflammatory cytokine modulation and endothelial permeability reduction. The company ...

Point-of-care testing identifies ARDS inflammatory subphenotypes in real time, offering insights into patient prognosis and mortality risks.

An initial trial suggests that a new drug, originally developed for use with cancer patients, could improve the survival of patients with acute respiratory distress syndrome (ARDS). The patients in ...

In a recent study published in PLoS ONE, researchers evaluated the outcomes and identified risk factors associated with the development of ARDS (acute respiratory distress syndrome) after SARS-CoV-2 ...

In a new report posted online in the American Journal of Respiratory and Critical Care Medicine, a global consensus conference of 32 critical care experts with broad international representation and ...